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Abstract
Chagas’ disease is caused by Trypanosoma cruzi, a protozoan transmitted to humans by blood-feeding insects, blood
transfusion or congenitally. Previous research led us to discover a parasite proline racemase (TcPRAC) and to establish its
validity as a target for the design of new chemotherapies against the disease, including its chronic form. A known inhibitor
of proline racemases, 2-pyrrolecarboxylic acid (PYC), is water-insoluble. We synthesized soluble pyrazole derivatives, but
they proved weak or inactive TcPRAC inhibitors. TcPRAC catalytic site is too small and constrained when bound to PYC to
allow efficient search for new inhibitors by virtual screening. Forty-nine intermediate conformations between the opened
enzyme structure and the closed liganded one were built by calculating a transition path with a method we developed. A
wider range of chemical compounds could dock in the partially opened intermediate active site models in silico. Four
models were selected for known substrates and weak inhibitors could dock in them and were used to screen chemical
libraries. Two identified soluble compounds, (E)-4-oxopent-2-enoic acid (OxoPA) and its derivative (E)-5-bromo-4-oxopent-2-
enoic acid (Br-OxoPA), are irreversible competitive inhibitors that presented stronger activity than PYC on TcPRAC. We show
here that increasing doses of OxoPA and Br-OxoPA hamper T. cruzi intracellular differentiation and fate in mammalian host
cells. Our data confirm that through to their binding mode, these molecules are interesting and promising as lead
compounds for the development of chemotherapies against diseases where active proline racemases play essential roles.
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Introduction
Chagas’ disease is one of the main causes of death by heart
failure in South and Central America. With at least 12 million
people infected and 100 million at risk, this is both a major health
concern and a socioeconomic problem in Latin America. As a
‘‘Most Neglected Disease’’, it is the third largest health burden
after malaria and schistosomiasis [1,2]. Of the affected adult
population, 10% will die from this chronic disease, which is
incurable and fatal in children aged less than two years. No
vaccine is available and current therapies are only effective in the
acute phases of the disease, while their success in chronic phases
remains a matter of debate. Recently, French Guyana experienced
an outbreak of the disease and this per se had a substantial impact
on European authorities that implemented eligibility criteria for
donors of blood, blood components, cells and tissues [3]. Recent
increases in congenital transmission, blood transfusion and
transplantation have drawn the attention of Public Health actors
both in Europe and the USA [4–6].
Until recently, only two drugs were available to treat infected
patients: Nifurtimox (3-methyl-N-[(E)-(5-nitrofuran-2-yl)methyli-
dene]thiomorpholin-4-amine-1,1-dioxide) and Benznidazole, a
nitroimidazole derivative (N-benzyl-2-(2-nitro-1H-imidazol-1-yl)a-
cetamide) [7]. Because of the side effects it causes, such as
neurological and gastrointestinal disorders the use of Nifurtimox
has been limited in favor of Benznidazole. Chagas disease
treatment, Benznidazole is today the only nitro-bearing medi-
cine [8]. Although its mechanism of action is not fully
elucidated, the drug is known to interfere with the redox cycles
of intracellular and extracellular parasite forms [9,10]. Several
toxic but reversible effects have been described such as general
allergic dermopathy, peripheral polyneuropathy, leucopenia,
anorexia and convulsions [8]. Major complications include
agranulocytosis and thrombopenic purple. In addition, Benzni-
dazole is mostly effective in the early stages while most
individuals afflicted with Chagas disease are diagnosed once
the chronic phases is already installed. Consequently, although
eradication of the parasite’s insect vector reduce its incidence in
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humans, new and more efficient treatments are needed and are
considered a priority [11,12].
Our previous research led to the identification and charac-
terization of several isoforms of T. cruzi proline racemases
(TcPRAC) [13,14]. Secreted and intracellular forms of the
enzyme were detected at all stages of the parasite life cycle. The
secreted form was shown to be a B-cell mitogen, which
contributes to parasite avoidance of the host immune system,
and to its persistence [13]. TcPRAC is a promising target for
the development of a new therapy against Chagas disease since
parasites are no longer viable when PRAC genes are knocked
down or more virulent if PRAC genes are over expressed [15].
Moreover, our current results using the 2-pyrrolecarboxylic acid
(PYC), the competitive (water insoluble) inhibitor of PRAC [16],
indicate that the infection of host cells in vitro reduces in a
clearly dose-dependent manner when PYC is added at parasite-
host cell interaction step in vitro. Lower mean numbers of
parasites per cell are also noted [17]. Interestingly, we
demonstrated that PYC binding closes the catalytic crevice
and impacts on the overall structure of the enzyme, precluding
its interaction with B-cells.
Here, we describe our approach to identifying new and more
effective TcPRAC inhibitors, which could be active in chronic
phases of Chagas disease. First, we used classical medicinal
chemistry approaches to improve PYC’s solubility and its
affinity for the PRAC catalytic pocket. Several PYC analogues
were synthesized and although they proved to be soluble in
water they presented little activity toward PRAC. Two of the
most soluble PYC derivatives, with a Chloro- or a Bromo- at C-
4 position, weakly inhibited TcPRAC. Next, since functional,
biophysical and structural data were available for TcPRAC
[18,19], virtual screening of chemical libraries to identify new
types of inhibitors seemed to be an option. However, previous
findings by crystallography and ITC calorimetry showed that
PYC is completely buried within an extremely small and specific
pocket in the ‘‘closed’’ ligand-bound structure of the enzyme
[18]. Therefore, attempts to use pharmacophores designed by
computational chemistry based on the crystallography of the
complex ‘‘TcPRAC/PYC’’ were unsuccessful because no ligand
has been identified through the virtual screening of several
databases of chemical compounds. Consequently, restricting our
investigations to catalytic-site based models limited the virtual
screening of chemical libraries to the identification of small and
metabolite-like compounds. To overcome these restrictions, we
built conformational transition paths between the closed
(complexed with the inhibitor) and opened (inhibitor-free)
shapes adopted by the TcPRAC, which yielded a number of
plausible intermediate structures of the catalytic site. Increas-
ingly opened and wider active site models were used for the
virtual screening of two accessible chemical libraries. Two of the
selected products, OxoPA and its derivative, Br-OxoPA [20],
were shown to be respectively 2- and 4-fold more potent than
PYC in inhibiting TcPRAC. Our results showed that OxoPA
and Br-OxoPA have lower apparent Ki values than PYC and
are irreversible competitive inhibitors. Finally, increasing doses
of OxoPA and Br-OxoPA in DMSO caused greater decreases
in mammalian host cell infection than those previously observed
with PYC [17]. These findings confirmed these compounds as
promising leads for the optimization and development of new
therapies against diseases where proline racemases play an
essential role.
Materials and Methods
Synthesis of Pyrazole Analogues
Figure 1 shows PYC (1), the two commercially available
imidazole-bearing analogues (2) Imidazole-4-carboxylic acid and
(3)1H-imidazole-2-carboxylic acid, and the pyrazole-bearing
analogues 4a–c. These were obtained from potassium permanga-
nate oxidation of the corresponding 3-methylpyrazoles using
previously described [21–23] and specific procedures [24].
Analogue 4a, 1H-pyrazole-3-carboxylic acid is called PZC here.
Analogues 4X-1H-pyrazole-3-carboxylic acids (X-PZC) for X = Cl
(4b, Cl-PZC), X = Br (4c, Br-PZC) X = CH2CH3 (5, Et-PZC) and
4-Cl-1-methyl-pyrazole-3-carboxylic acid (13, M-Cl-PZC) bearing
faint activity are reported in Table 1. Other 3-carboxylpyrazoles
derivatives bearing larger substituted groups on carbons 4 and 5
were also prepared but were all devoid of effects in the
racemization assays (not shown).
Building a Transition Path between Open and Closed
Forms of TcPRAC and Virtual Screening
The structure of hemi-bounded TcPRAC (1W62 hemi complex
PDB) is asymmetric and shows one closed subunit binding PYC
(chain A), and one unbound opened subunit (chain B) [18]. By
swapping the chain labels and reorientation on the original
structure we built an inverted structure where chain A is opened
and chain B is closed (see Figure 2A). Internal coordinates and
Cartesian coordinates of the two extreme structures were
compared to remove unnecessary symmetric side chain flips
between the two structures. Then, we built a transition path
connecting the two structures, hence modeling opening of chain A
and closing of chain B when moving from the original structure to
the inverted one (see schematic view in Figure 2B). For that, we
used the ‘‘Path Optimization and Exploration’’ approach (POE)
described in ref. [25]. This approach iteratively uses the
Conjugated Peak Refinement (CPR) [26] method of the
CHARMM program [27] to refine the path, explore possible
shorter local paths and reassembles them to reconstruct the whole
path. The transition path was built on all atomic degrees of
freedom (here 19488), as a curved trajectory formed by a series of
N (here 49 at the end of the procedure) ordered and low energy
intermediate states (Xi, i in [1,.,N]) avoiding energetic barriers.
Following CPR construct, it ensures the absence of ‘‘hidden’’
barriers by probing the energy of structures along a straight line
between consecutive intermediates of the path ([Xi,Xi+1], with i in
[1,.,N21]), and checks that it is lower than a given (low) threshold
(E[(1–l)Xi+lXi+1], Emax, l in [0,1]). To facilitate the first
iteration, the procedure was initiated with a Molecular Dynamics
(MD) trajectory starting from the original structure and drawn
towards the inverted structure by a linear constraint of 0.5 kcal/
Figure 1. Structure of initial compounds and analogues. (1) PYC
and its nitrogen-bearing analogues: (2) Imidazole-4-carboxylic acid, (3)
1-H-Imidazole-2-carboxylic acid and (4a) PZC, (4b) Cl-PZC and (4c) Br-
PZC.
doi:10.1371/journal.pone.0060955.g001
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mol/A˚/atom. MD was 200,000 steps long recorded every 100
steps with a Langevin thermostat at 300 K and a friction
coefficient of 100 ps21 to remove excess heat. The solvent is
modeled implicitly for CPR is an optimization method and, thus
requires instantaneous solvent equilibration at room temperature
while the structure energy is being minimized, which corresponds
to a low temperature. The analytical continuum electrostatics
(ACE2) potential [28] was used with default dielectric constants (1
inside the protein and 80 outside) to avoid formation of artifactual
cavities. POE includes various procedures above simple CPR to
reduce the number of intermediates for the same level of
optimization (all intermediate have energies lower than a given
threshold, here 234000 kcal/mol). (i) Intermediate structures are
systematically removed if any linear interpolations between
remaining consecutive structures are still below an energy
threshold (-34000 kcal/mol) in a procedure implemented as
‘‘backward reduction’’ [25]. (ii) Sub-paths are recalculated with
CPR between intermediate Xi and Xj, j2i.nmin, at distance
dij,dmax, when the latter are separated by a sequence interme-
diate Xi+1,…Xj21 covering a length (li,j = di,i+1+…+dj21,j) that is K
time larger than dij. K, dmax and nmin are adjusted according to
path refinement according to computer resources available (e.g.
maintain the list of i,j pairs lower than 1000). Distance between Xi
and Xj, di,j is the RMS difference between respective coordinates
expressed in A˚. In early phases the path is rugged and K has to be
set at high level, say 5, dmax low, say 1.5 A˚, and nmin high, say 10
or 20. At late phases the path is smoother, the number of pairs
fulfilling the early criteria decreases and K can be set to lower
values, say 1.5, dmax higher, say 2–3 A˚, and nmin lower say 5. A
Recalculated sub-path replaces the original one when its
maximum energy is lower or equal to that of the replaced sub-
path and the number of intermediates it contains is lower.
The volume of the cavity was calculated with a cavity search
program developed in the laboratory and described in [29], but
without outer sphere limit. Within the cavity, the points accessible
to the center of the probe sphere are labeled (i.e. points excluded
from the protein atoms when their canonical exclusion radii had
been incremented by the solvent probe sphere radius). The cavity
extension is calculated as the maximum distance between the latter
points. Xmgrace was used to prepare the graphics of Figures 3A,
3B and 3C and Figure 4A [http://plasma-gate.weizmann.ac.il/
Grace/]. Ligand sizes, lmax, were measured on canonical
conformers in the computer graphic program VMD, which was
also used to prepare Figure 2A and Figure 4B [30].
Four intermediate structures from the transition path were
selected using the docking scores of known ligands and weak
inhibitors, and structural inspection. The FlexX 2.0.3 program
was used [31] with the default scoring function as recommended
by the provider for novel type of binding site and because the goal
was to select different type of compounds than the known ones.
Acidic amino acids and amines were deprotonated and protonated
respectively. Dockings were performed twice with His 132
protonated on Nd1 and then, on Ne2. Doubly protonated His
132 gave similar geometries in redocking than His 132 singly
protonated on Nd1 (pointing inwards the binding site) and was not
used for screening. Compounds were assigned their best score
obtained with the two His 132 protonation states. The 2D
compound structure definition files (sdf) from two accessible
chemical libraries: ChemDiv, Inc (San Diego, California, USA;
630,000 compounds at the time) and Chimiothe`que Nationale
(CNRS, France; 31,000 compounds at the time; library devoted to
chemical diversity and not only to drugable compounds.) were
processed with the CORINA program [32] to develop their 3D
structure and add hydrogen atoms. No filters were applied to the
library of compounds as their combination with the little size of the
targeted pocket would most likely have obliterated any chance of
finding discernible inhibitors. Ligands were selected if their FlexX
score was below 220, 220, 225 and 233, respectively for
transition path structures 1, 4, 10 and 49. Cutoff values were
adjusted to trim selection to similar number of compounds as a
compensation of the differences in volume and limit the number of
candidates. (see Figure 3C; 219, 345, 385 and 430 compounds
thus selected respectively). The compounds from the different
screenings were combined (1199 unique compounds and 180
found more than once), clustered by chemical similarity (linear
fingerprints) with an UPGMA classification and a 0.55 threshold
in the ICM program [33], and the best compound in each cluster
was selected.
Preparation of Recombinant TcPRAC
Recombinant Trypanosoma cruzi proline racemase (EC 5.1.1.4)
was produced in E. Coli BL21 (DE3) (Invitrogen) and purified by
immobilized metal affinity chromatography on nickel columns, as
previously described [13].
Racemization of L-Proline and Inhibition Assays
Optimum Proline racemization conditions for TcPRAC were
determined using 10–300 mM L-Proline in 0.2 M NaOAc over a
range of pH values, as described [13] and L- to D- proline
conversion took place in 1.5 mL reaction. Concentrations of D-
proline formed were determined by optical rotation of the solution
at 365 nm in a 10 cm optical path cell, thermostated at 37uC,
using a polarimeter (Perkin Elmer 241 MC). Assays were also
performed into microtiter plates (100 mL), as follows: dilutions of
Table 1. PYC derivatives and their capacity to inhibit* TcPRAC.
Compound, Name (Abbreviation and #)** Solubility Inhibition Ki (mM)***
Pyrrole-2-carboxylic acid (PYC, 1) Ethanol ++++++ 6–10
Pyrazole-3-carboxylic acid (PZC, 4a) Water +/2 .2000
4-Chloro-pyrazole-3-carboxylic acid (Cl-PZC, 4b) Water + 300
4-Bromo-pyrazole-3-carboxylic acid (Br-PZC, 4c) Water + 1000
4-Ethyl-pyrazole-3-carboxylic acid (Et-PZC, 5) Water +/2 .2000
4-Chloro-5-methyl-pyrazole-3-carboxylic acid (M-Cl-PZC) Ethanol +/2 .2000
*As determined by polarimetry and DAAO methodologies (see Materials and Methods).
**See Supporting Table 1 for compound formula.
***As determined by classical Michaelian approaches.
doi:10.1371/journal.pone.0060955.t001
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L- Proline (40 mM to 2.5 mM) in 0.2 M sodium acetate pH 6.0
and 0.25 mM TcPRAC were loaded into microtiter plate wells
with 0–20 mM PYC or similar concentrations of potential
inhibitors. Controls omitted TcPRAC and/or PYC. The micro-
titer plates were incubated for 30 minutes at 37uC. The enzyme
was inactivated by heating in a microwave oven for 15 s at 900
Watts and shifting the pH to 8.3 by adding 6.8 mL of 0.235 M
sodium pyrophosphate. The presence of D-Proline was tested in
50 mL from each well using the D-amino oxidase - Horse Radish
Peroxidase/OPD combined test [34]. Interference caused by the
possible reactivity of amino acid L-forms with DAAOx was taken
into account by using standards consisting of serial dilutions of an
equimolar mixture of D- and L-proline ranging from 0 to 10 mM
(10 mM total). For instance, DAAOx reacts with L-Proline 300
times slower than with D-Proline. Optical densities, OD490 nm –
OD650 nm were recorded on a microtiter plate reader (Molecular
Devices), and the signals from the blank control wells were
deducted.
Parasites, Cell Cultures and Cellular Extracts
Cell culture-derived trypomastigotes from T. cruzi CL Brener
(clone F11-F5) were isolated from the supernatant of bulk cultures
Figure 2. PYC-induced structural rearrangement of TcPRAC prompted a virtual screening strategy. (A) In the crystal structure (1W62.PDB),
the substrate-binding cavity of the ‘‘closed’’ protomer, shown as red ribbons and cylinders, is completely buried, as illustrated by the small green
volume surrounding PYC whose nitrogen, oxygen and carbon appear as blue, red and cyan small spheres, respectively. In the absence of PYC, the
TcPRAC protomer has a more relaxed, open structure, shown as blue ribbons and cylinders, with the void volume of the active site accessible from
the bulk solvent shown in green. (B) Schematic overview of the virtual screening strategy. The 3D structure of the hemi saturated complex shown in A
is represented by circles of the same color on the left. It was used to build the symmetric form of the complex as depicted by the circles on the right.
Molecular mechanics and molecular dynamics were used to model TcPRAC motion (horizontal arrow) triggered by inhibitor binding. Known (weak)
inhibitors derived from PYC were used to select intermediate conformations on the basis of their docking scores.
doi:10.1371/journal.pone.0060955.g002
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Figure 3. Transition path characteristics. (A) Energy profile and metric quantities for the TcPRAC transition path. The energy profile (full line)
shows that the intermediate states have low energy and do not present any energy barriers. Dotted and dashed lines show the distance from the first
structure (d1,i) and the cumulative distance covered from the first structure (l1,i), respectively (RMS in A˚, see Material and Methods). Little swerving was
necessary to avoid the energy barriers. The points corresponding to the intermediate structures used in the screening are marked by crosses. (B)
Scores of known ligands, synthesized analogues, and new inhibitors when docked in the selected binding site models. Br-OxoPA could not be docked
Proline Racemase Inhibitors
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of green monkey Vero kidney cells previously infected with
bloodstream trypomastigotes [35]. Known numbers of parasites,
adherent infected cells and uninfected cell controls were lysed with
0.1 mL of 0.05% Tween 20 solution in sterile distilled water and
the lysates were frozen. Vero cells were seeded in LabTek slides
(56104 cells/well) in RPMI 1640 medium/5% FCS and kept at
37uC, 5% CO2. To test the effect of the inhibitors in the initial
steps of the host-parasite interaction, cultures were infected for
17 h at 37uC at a 10:1 parasite/cell ratio with or without
increasing doses of freshly prepared dilutions (0–30 mM) of
OxoPA, Br-OxoPA [20], or (10–1000 mM) of PYC, previously
dissolved in DMSO. To test the effect of the inhibitors on the
parasite intracellular cycle, cultures were infected at 37uC for 17
hours without inhibitors, washed three times to eliminate
extracellular parasites then incubated for up to 48 hours with
fresh medium containing different dilutions of the compounds. All
cultures were then washed with PBS, fixed and stained with
Giemsa. The number of infected host cells was recorded along
with the number of parasites per infected cell in at least 400 host
cells, in duplicate experiments. Results were expressed as the
endocytic index (EI) resulting from the product of the percentage
of infected cells and the mean number of parasites per infected cell
[36]. Control cultures were incubated in medium alone or with
equal DMSO concentrations.
Capture ELISA
Flat-bottomed microtiter plates (Nunc, Denmark) were coated
overnight at 4uC with rabbit anti-T. cruzi polyclonal antibodies
and further blocked for 4 h at room temperature (RT) with 1%
BSA, 0.05% Tween 20 in PBS. After washings, lysate samples
from infected or control Vero cultures, or from T. cruzi, were then
added and incubated at 4uC for 18 h. Plates were washed with
PBS-Tween and incubated for 2 h at RT with polyclonal mouse
anti-T. cruzi chronic serum, washed again and incubated for 1 h at
RT with HRP-secondary antibodies. Reactions were revealed with
1 mg/mL OPD/0.05 M citrate/phosphate buffer, and appropri-
ately stopped with 3 M HCl. Optical densities were determined in
a spectrophotometer at 450 nm and 650 nm, and analyzed by
Softmax Pro software.
Results
Two Synthesized PYC Analogues are New (but Weak)
Inhibitors of Proline Racemase
We used conventional medicinal chemistry approaches in an
attempt to improve the solubility of the proline racemase
competitive inhibitor pyrrole carboxylic acid (PYC) and its affinity
for the TcPRAC catalytic pocket (Figure 1, Table 1 and Table S1).
Primarily, several pyrazole analogues were synthesized [23], [24],
[37], but while some showed better solubility in water by
qualitative standards, none showed greater affinity for TcPRAC
than PYC (Ki = 6–10 mM). Two of the soluble PYC derivatives,
namely 4-chloro-1H-pyrazole-3-carboxylic acid (Cl-PZC, 4b) and
4-bromo-1H-pyrazole-3-carboxylic acid (Br-PZC, 4c), weakly
inhibited TcPRAC (Ki<0.3 mM and 1 mM, respectively). Two
other derivatives Ethyl-1H-pyrazole-3-carboxylic acid (Et-PZC, 5)
and 4-chloro-5-methyl-1H-pyrazole-3-carboxylic acid (M-Cl-PZC,
13) seemed to exert weak inhibition (Ki.2 mM). These results are
in agreement with the failure of the classical docking approach.
Hence, the synthesis of a transition state analogue, more potent
than PYC, is certainly not the best way to find an efficient
TcPRAC inhibitor for Chagas disease treatment.
Building Intermediate TcPRAC Conformations to Broaden
the Chemoinformatic Search for Inhibitors
The TcPRAC catalytic site is small (the volume of a proline) and
makes extremely specific contacts with the ligand [18]. Several
pharmacophores were designed based on the features of the crystal
PYC-bound to the catalytic site of TcPRAC and used for the
virtual screening of several chemical libraries. However, the search
has identified only small, metabolite-like molecules, and failed to
identify any new inhibitors (Minoprio, P. and Afshar, M.,
unpublished; see Table S2). To overcome this limitation, we built
plausible intermediate structures to model the functional transition
path of the TcPRAC between its closed/liganded and its opened/
unliganded forms [18] (see Figure 2A). Use of intermediate
structures of the catalytic site broadened the search to larger and
chemically more diverse inhibitor candidates.
Molecular mechanics methods detailed in Material and
Methods section were used to infer the plausible conformational
intermediate states adopted by TcPRAC when switching between
the two symmetric hemi-bound states found in the 1W62 PDB
entry (Figure 2B). The transition proved to be relatively simple
compared with other cases (e.g. [38], [25]) and the process
converged after 3 full cycles of the procedure, described in
Materials and Methods section. The resulting path consisted of 49
low-energy structures (or conformations) (see Figure 3A). The two
subunits followed different transition paths, offering a larger
number of possible intermediate conformations for the active site
(96 = 4962–2). Thus, the path is asymmetric and its length (l1,49) is
4.78 A˚, to connect the two extreme conformations at 2.62 A˚
distance (d1,49) (see Figure 3A). The ratio of the length over the
distance for the whole path (4.78/2.62 = 1.82) indicates that the
transition path is moderately, but still significantly, curved (a linear
transition would give a ratio of 1 and a hemi-circle, p/2).
Known ligands and analogues, PYC, L-PRO, D-PRO, Cl-PZC,
Br-PZC, Et-PZC and M-Cl-PZC were docked in both catalytic
sites on each of the 49 conformations using FlexX [30]. The
in the crystallographic structure and its score in the fourth conformation is circled. The score threshold that was chosen in the subsequent virtual
screening phase for ligand selection is indicated by a dashed line and the exclusion region is striped. Transition path characteristics. (A) Energy profile
and metric quantities for the TcPRAC transition path. The energy profile (full line) shows that the intermediate states have low energy and do not
present any energy barriers. Dotted and dashed lines show the distance from the first structure (d1,i) and the cumulative distance covered from the
first structure (l1,i), respectively (RMS in A˚, see Material and Methods). Little swerving was necessary to avoid the energy barriers. The points
corresponding to the intermediate structures used in the screening are marked by crosses. (B) Scores of known ligands, synthesized analogues, and
new inhibitors when docked in the selected binding site models. Br-OxoPA could not be docked in the crystallographic structure and its score in the
fourth conformation is circled. The score threshold that was chosen in the subsequent virtual screening phase for ligand selection is indicated by a
dashed line and the exclusion region is striped. (C) Cavity volume and extension in transition path intermediates, and docked molecules properties.
Volume and extension are calculated as explained in Material and Methods. The volume is displayed by the thin line curve. Cavity extension is
displayed by the thick curve and crosses mark intermediates that were used for virtual screening. The extension of PYC is shown by the horizontal
line, that of OxoPA in all-trans conformation is shown by the horizontal dashed line. The extension of BrOxoPA in all-trans conformation is given in
dotted line for two extreme rotamers on the C4–C5 bond. The average molecular weight of the library compounds successfully docked in conformers
1, 4 and 10 is displayed by filled circles. For clarity, the average mass has been divided by 2 to fit the same scale as the cavity volume.
doi:10.1371/journal.pone.0060955.g003
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pocket corresponding to Chain A in the 1W62 PDB entry gave the
best results both in terms of docking score and RMSD in the case
of PYC. Figure 3B gives the main scores obtained with the 4
selected docking models (i.e. 1, 4, 10 and 49). As the goal was to
extend docking to other types of ligands, no attempt was made to
optimize the docking of all those compounds. Conformation 4 was
retained as it gave good scores for some ligands that did not score
well in conformation 1 (closed catalytic site for chain A in the
1W62 PDB entry), especially for Et-PZC which is one of the
largest known ligand and which had its best score in conformation
4. Conformation 10 gave favorable scores compared to neighbor-
ing conformations, and was the last ‘‘closed conformation’’
(subsequent conformations had opened access to bulk solvent)
and showed an organized hydrogen bond network at the catalytic
site, which was not the case for subsequent conformations. Hence,
it was selected as it was expected to allow the capture of larger and
more diverse ligands although the known ligands which are small
could not bind so tightly in this slightly opened conformation. The
volume and maximum extension of the cavities for chain A, which
appeared the most interesting for docking, are shown in Figure 3C.
Beyond intermediate number 10, the cavity is opened to the bulk
solvent so its extension and volume are infinite according to the
way these quantities are calculated. Conformations 4 and 10
together with the closed (1) and opened (49) crystallographic
structures were selected as docking models for the virtual screening
(Figure 4A).
Virtual Screening, Candidate Ligand Selection and
Testing
The 4 docking models were used in the two His 132 protonation
states for the virtual screening of 31,000 compounds from the
Chimiothe`que Nationale (CN) and 630,000 compounds from the
ChemDiv Chemical library (ChemDiv). The first two conforma-
tions led to the selection of small ligands, while conformations 10
and 49 selected compounds that were larger than PYC. This was
reflected by the average molecular weight of the successfully
docked compound in cavity 1, 4 and 10 (see Figure 3C). The
average mass of compounds successfully docked in cavity 49
(382 Da = 19162 Da) is more due to average mass of molecules in
libraries than to the size of the cavity, which is unlimited.
Noticeably however, conformation 4 selected slightly larger and
heavier ligands than conformation 1. Following the procedure
explained in Materials and Methods, 113 compounds were
ordered from the ChemDiv and 37 from the CN and respectively
104 (92%) and 26 (70%) compounds were made available and
tested for their ability to inhibit TcPRAC.
Only two novel TcPRAC inhibitors, both provided by the CN,
were identified among these (Figure 4B). These compounds, both
poorly reactive Michael acceptors - OxoPA (C5H6O3, MW
114,10, lmax = 6.07 A˚, CSID:4515976, http://www.chemspider.
com/Chemical-Structure.4515976.html) and its derivative BrOx-
oPA (C5H5O3Br, MW 193,00, lmax = 6.10 to 6.80 A˚, [20]
(Figure 4B) proved to be more potent than PYC (C5H4NO2,
MW 110.09, lmax = 4,60 A˚), in terms of TcPRAC inhibition. Thus,
based on a DAAOx test [34], equivalent concentrations of OxoPA
and BrOxoPA inhibit more than 5 times the conversion of L- into
D- proline catalyzed by TcPRAC than that obtained with PYC
(Table 2). Correspondingly, 3 mM of OxoPA and 2.5 mM of
BrOxoPA are required for 50% inhibition (IC50) of TcPRAC
in vitro, as compared to 10 mM of PYC, as determined by
polarimetry (Table 3).
Figure 4. Selection of active site conformations for virtual screening. (A) Four of the 49 conformations defining the path were selected for
virtual screening. Protein secondary structures are shown schematically as in Figure 2. Transparent green spheres show the enclosed void volume of
the pocket, with the ligand inside the first three structures (opaque green). (B) Structure of the two identified novel inhibitors of TcPRAC.
doi:10.1371/journal.pone.0060955.g004
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Kinetic reaction assays using fixed amounts of dimeric PRAC
(22 mg –0.24 mM final), 40 mM substrate and 10 mM of the
identified inhibitors were performed to characterize their effect on
enzymatic activity (Figure 5). PYC, the transition state analogue of
proline, slows the racemization of L-proline (,37% of original
speed in these conditions). As it has been shown before PYC is a
classical competitive and reversible TcPRAC inhibitor and such as
the reaction proceeds until racemic mixture is obtained [16]. The
establishment of PYC inhibition is fast as shown by the slope of the
curve at the origin and promptly reaches the steady-state
(Figure 5A). In contrast, as compared with the curve obtained
with PYC, TcPRAC inhibition by OxoPA and BrOxoPA appears
to be time-dependent since the initial velocity is not correlated
with the global reduction of D-proline formation. For both OxoPA
and BrOxoPA the curves of enzyme reaction progress are not
linear with a final velocity close to zero. The rate of enzyme
inactivation observed is faster for BrOxoPA than for OxoPA, since
the plateau is reached at 250 seconds for BrOxoPA when it
requires 350 seconds for OxoPA. The rate of inactivation reaction
and the slope of the inhibition curves obtained with these two
compounds suggest that these molecules present distinct affinities
and/or reactivity for the catalytic site of the enzyme. In addition,
excess of substrate (300 mM of L- proline, data not shown)
induced observable protection from inactivation by these two
compounds, which suggested that the inactivation process took
place in the catalytic pocket. To further characterize the mode of
action of this two molecules, the enzyme was pre-incubated
(concentration 22 mg 2 3,6 mM) with different concentration of
inhibitor, for 5 or 10 min to determine inhibition dependence to
inhibitor concentration and pre-incubation time. Then, the
reaction mixture was diluted 15 fold and residual activity was
determined in an excess of substrate (300 mM of L- proline). As
can be seen in Figure 5B, BrOxoPA inactivation is faster than the
one observed for OxoPA and in both cases the rates of inactivation
are dependent on the inactivator concentration and time,
suggesting a classical irreversible reaction. Besides, irrespective of
the fact that BrOxoPA and OxoPA bind to the catalytic site and
cause rapid or slow inactivation of the enzyme both compounds
are very strong and irreversible TcPRAC inhibitors. The presence
in OxoPA and BrOxoPA of a carboxylic acid function like in
Proline and PYC is an important element of recognition of these
compounds. Furthermore, the sp2 C-2 carbon of both OxoPA and
BrOxoPA, matching the inverted Ca of the proline and the sp2 C-
2 of PYC, is an electrophilic center that can be covalently bounded
with a nucleophylic amino acid such as a cysteine residue. One can
suppose that the carboxylic acid moiety holds the electrophilic C-2
reacting group at a mutual distance of the two cysteine residues
(Cys-130 and Cys-270 that are involved in the proline isomeri-
sation), which highly favors the reaction. In fact, in the docking
leading to the selection of the OxoPA and BrOxoPA, their
carboxylate group was close to the moieties making hydrogen
bonds to the PYC carboxylate in the X-ray structure. Noticeably,
the FlexX program, which is based on fragmentation-reassembly
of the ligand, rebuilt ligands in poses with a cis C3–C4 bond
(Figure 6). Those shorter conformers allowed positioning of the C2
atom close to the middle of the pair of catalytic sulfur atoms with
an occupied volume slightly larger than that of the modeled PYC
(drawn in lines; lmax = 5.27 and 5.38). Although docking poses are
usually poorly reliable, this shows that those molecules could make
highly specific interactions with limited adjustment. Finally, we
pursue enzyme crystallization with OxoPA and BrOxoPA to
elucidate whether they are covalently attached to target catalytic
residues of TcPRAC (experiment in progress).
Mammalian Cell Invasion by the Parasite is Hampered by
New Inhibitors of TcPRAC
To verify the potential of these new PRAC inhibitors as lead
compounds in drug design strategies, we compared their effects on
cultures of host Vero cells infected or not with T. cruzi, with that of
PYC. Our results showed that when increasing PYC concentra-
tions (3, 10 mM, 100 mM, 1000 mM) are added concomitantly with
trypomastigotes and host cells in vitro, a clear dose-dependent effect
was noted resulting in fewer infected host cells, and lower mean
numbers of parasites per infected host cell (Table 4). In
comparison, lower doses of OxoPA or Br-OxoPA (100- and 30-
fold, respectively) were necessary to obtain the same endocytic
index (EI) as that observed with culture cells treated with PYC. For
instance, while control samples treated with comparable amounts
of DMSO did not show any particular alterations, equivalent EI
were observed for 1000 mM PYC and 10 mM OxoPA or 30 mM of
Br-OxoPA. It is noteworthy that neither OxoPA nor Br-OxoPA
considerably affected the viability of non infected Vero cells, which
maintained adhesion to the support at the tested concentrations (3,
10 and 30 mM). To confirm the effect of the inhibitors in the initial
steps of the host-parasite interaction (parasite uptake), cultures
were infected for 17 h at 37uC at a 10: 1 parasite/cell ratio with or
without increasing doses of freshly prepared dilutions (5, 10,
30 mM) of OxoPA, Br-OxoPA, or (10, 100, 1000 mM) of PYC,
previously dissolved in DMSO and further analyzed by capture
ELISA. Although no particular differences were observed in
cultures treated with PYC diluted in DMSO, as in Table 4 a dose
dependent inhibition of cellular infection was induced by both
inhibitors, most particularly with Br-OxoPA. To determine
whether the treatment of these cultures with the new compounds
would indeed affect intracellular TcPRAC and as such interfere
with parasite intracellular fate cells were then washed after parasite
uptake and the same ligand concentrations as above (10 mM 2
30 mM) were added to the cultures in fresh medium. The degree of
infection was determined over 48 hours by capture ELISA. As
Table 2. Two new compounds are more potent inhibitors of
TcPRAC than PYC.
Inhibitor
Inhibitor
Concentration D-Proline formed
(–) (–) 5.0 mM
PYC 10 mM 2.4 mM (IC50)
OxoPA 10 mM ,0.3 mM
Br-OxoPA 10 mM ,0.3 mM
doi:10.1371/journal.pone.0060955.t002
Table 3. Inhibition of TcPRAC proline racemization measured
by polarimetry.
Inhibitor
Inhibitor
concentration
Racemization
Inhibition
(–) (–) 0.0%
PYC 10.0 mM 56.9%
OxoPA 3.0 mM 50.0%
Br-OxoPA 10.0 mM 81.3%
Br-OxoPA 2.5 mM 50.0%
doi:10.1371/journal.pone.0060955.t003
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expected, the number of parasites per well decreased in a dose-
dependent manner (Figure 7). In vitro and in vivo experiments using
mutant parasites that carry the luciferase gene are now in progress
to support those data. In conclusion, these experiments indicate
that TcPRAC inhibition by OxoPA and Br-OxoPA affects both
cellular infection by T. cruzi and parasite development in tissues.
Discussion
The data presented herein substantiate previous findings
showing that PRAC plays a role in both T. cruzi development
and infectivity and further support its use as a original target for
the development of a new chemotherapy against Chagas’ disease
[7,15,39,40].
Modeling the protein functional trans-conformation by molec-
ular mechanics and using the plausible intermediate conformers
thus built for virtual screening happened to be a fruitful approach
since OxoPA and Br-OxoPA would not have been selected if the
screening had been performed on the crystallographic structure
alone. This puts forward and substantiates the idea that targeting
putative functional intermediate structures could open new doors
in rational drug design and gives access to molecules with novel
mode of action [25], [41]. However, intermediate structures build
by modeling methods remain hypothetical and many examples
such as the work presented here and others [25], [41] will be
necessary to fully establish this type of approach. Other methods to
explore structural transition such as umbrella sampling and other
free energy based methods could be used. However, they require a
previous knowledge of a relevant geometrical description of the
mechanism (e.g. by collective variables), and the transition path
model is given as an ensemble of millions intermediate structures,
which may be difficult to exploit in a virtual screening approach.
POE (see Materials & Methods) almost unavoidably requires use
of an implicit solvent model to ensure immediate and room
temperature equilibration of the latter in the context of
Figure 5. Kinetics of D-proline formation with time in the presence or absence of TcPRAC inhibitors. (A) Concentrations of D-proline
formed were determined by polarimetry in reaction assays containing 0.15 mM of TcPRAC and 40 mM L proline (see Material and Methods). Optical
rotation was measured every 10 s for 8 min, with 10 mM PYC competitive inhibitor (black circles), 10 mM OxoPA (black squares) and 10 mM Br-OxoPA
(black triangles), or without inhibitor (white circles). (B) Percentage of residual activity after pre-incubation of the enzyme with different
concentrations of OxoPA and BrOxoPA for 5 minutes (upper panel) and 10 minutes (lower panel).
doi:10.1371/journal.pone.0060955.g005
Figure 6. Close view of the docking pose of BrOxoPA and
OxoPa in configuration 4. Enzyme residues are displayed in
‘‘licorice’’ with CPK colors and Carbons in cyan. Small spheres highlight
sulfur atoms. Same representation with carbon in grey for inhibitor
docking pose. Atoms forming bonds with the carboxylate of PYC in
1W62 structure are connected to corresponding pose inhibitor atoms.
PYC molecule modeled by superposition of carboxylate and C2 atoms
on that of BrOxoPA is displayed in lines, carbons in cyan.
doi:10.1371/journal.pone.0060955.g006
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optimization. ACE2 is a highly robust generalized Born implicit
model. It is approximately 10 times slower that fast implicit models
like sigmoidal electrostatic models or EEF1 implemented in
CHARMM [42], but it is also about 10 times faster than
conventional explicit water simulations. It has proved to be very
effective with POE since optimization performs better than with
cruder models with better convergence properties and building of
better conformations, which is important for docking [25].
Interestingly, the keto-acids compounds identified in this work
and acting as Michael acceptors like in many drugs actually in
development [43,44], differ considerably from PYC and proline
residues. Noticeably, many drugs appear to be covalent inhibitors
and up to 35% of the current drug targets could be covalently
inhibited although the discovery programs were not seeking such
mechanism [45]. The suitability of developing covalent inhibitors
appears to be favorably reconsidered [46]. Noteworthy, the
current inhibitors would have been discarded if a classical
‘‘drug-like’’ filter had been applied. It had been decided not to
apply such classical filters due to small size of the targeted site and
the previous unsuccessful attempts to identify TcPRAC inhibitor,
substantiating the idea that no chances to identify an inhibitor for
this unconventional site should be put aside. Additionally, it would
have been difficult to identify those compounds by classical
medical chemistry or QSAR methods. Another interesting
contextual consideration to have, bearing in mind the suitability
of covalent drugs, is that virtual screening methods are mostly
conceived for non covalent interactions. In the current work, a
slight leap helped us in finding the current inhibitors. The detailed
topology of the molecule described in the virtual libraries did not
clearly specified the conjugated nature of the molecule and the
program most likely fragmented the molecule between C3 and C4
before reconstruction in the cis conformation allowing closer
superposition with PYC structure (e.g. Figure 6). We maintained
this compound in the order list, considering that some spontaneous
isomerization could occur. This reconstruction together with the
larger volume offered in conformation 4 probably give sufficient
flexibility to accommodate the current compounds, hence
effectively enlarging the chemical search space.
OxoPA and Br-OxoPA not only inhibit TcPRAC biochemically
but also have effects both on cellular infection by T. cruzi and on
parasite intracellular development. This shows their efficacy
against essential parasite processes and consequently supports
their therapeutic potential. These compounds have also been
shown to reach their intracellular target, clearly demonstrating
their diffusion through both cell and parasite membranes. Finally,
no significant, detectable toxicity against mammalian cells was
observed in vitro. Altogether, these properties indicate that OxoPA
and Br-OxoPA are promising leads for the development of new
therapies against the chronic phases of the disease.
Ongoing experiments aim to design and synthesize even more
effective OxoPA and Br-OxoPA derivatives with improved affinity
and specificity for TcPRAC and appropriate pharmacokinetic
properties. One line of improvement is to synthesize compounds
Figure 7. Effects of TcPRAC inhibition by OxoPA and BrOxoPA on parasite interaction with host cells in vitro. Vero cells cultures were
infected for 17 h at 37uC with cultured trypomastigotes at a 10:1 parasite/cell ratio then washed and incubated for 17 h with 0, 100 and 1000 mM of
PYC, or 0, 10 and 30 mM OxoPA or Br-OxoPA in fresh medium. Total parasite numbers/culture were estimated by capture ELISA.
doi:10.1371/journal.pone.0060955.g007
Table 4. New inhibitors induce a decrease of cellular uptake
of T. cruzi.
Inhibitor concentration (mM)
Compound 0 3 10 30 100 1000
Endocytic index
(EI)
PYC 45 nd 44 nd 30 25
OxoPA 57 42 23 21 nd nd
Br-OxoPA 57 78 42 29 nd nd
doi:10.1371/journal.pone.0060955.t004
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with lower electrophilic reactivity to decrease potential sources of
toxicity in a complex physiological environment. From these two
promising inhibitors, a set of candidate structures can be
synthesized that will improve both the non-covalent binding
affinity and the positioning of the electrophilic site with respect to
the nucleophylic partner (Cys residues) in the catalytic site to
optimize potency and selectivity. The nature of the electrophilic
moiety will be investigated. Ideally, this electrophile should be
poorly reactive with nucleophiles under physiological conditions
but upon appropriate orientation should selectively react in the
catalytic site. A key step in this process is to refine the
crystallographic structures of the enzyme complexed with these
inhibitors to better support medicinal chemistry approach. Such
studies would strengthen the structural hypotheses used to identify
these compounds and provide more robust data for the lead
optimization process. Since we have recently shown that
important pathogens of the T. cruzi family [47] and also
nosocomial bacteria produce functional proline racemases [48],
our data suggest that these chemicals may also be useful in other
diseases where proline racemases are vital.
Supporting Information
Table S1 Pyrazole-bearing analogues of PYC were
synthesized by conventional and specific procedures,
as described in the Material and Methods. Compound
abbreviations used throughout the manuscript text are shown in
parenthesis.
(ZIP)
Table S2 Initial attempts to identify inhibitors based on
a pharmacophoric approach under TcPRAC crystallo-
graphic structure insight. Six pharmacophoric models were
built and tested (software Catalyst 4.11 (1252), Acceryls Software,
Inc) with by then known weak inhibitors: PYC, PZC, Cl-PZC, Br-
PZC and non-inhibitor but also hydro soluble related compounds
built by medicinal chemistry (see Materials and Methods). The
selectivity of the pharmacophore and the three-dimensional
analysis in terms of size and volume of the TcPRAC catalytic
site cavity (1W61 and 1W62 PDB codes, publicly available) guided
the choice. The binding of PYC to TcPRAC is maintained by a
network of hydrophobic and hydrophylic interactions, as it has
been reported in details by crystallographic studies [18]. An initial
pharmacophore was automatically generated based on PYC using
the ‘‘Hypogen’’ procedure. It displayed 1 hydrogen bond donor, 2
hydrogen bond acceptors and 1 aromatic ring features. This
pharmacophore was refined incrementally by the study of the
TcPRAC catalytic site structure to avoid numbers of false positive/
negatives in the known inhibitor/non-inhibitor set. Hence, the
analysis of the best inhibitor, PYC, showed that Phe-290 benzene
ring forming one of the binding pocket wall lead to steric
constraints that could disallow the binding of larger molecules and
impose hydrophobicity restrictions. Thus, the overlay of the
pharmacophore 3D-coordinates on the PYC/TcPRAC complex
3D structure guided the definition and constraints of the exclusion
volume and shape added to the initial pharmacophore. More than
2 200 K molecules from 7 chemical compound libraries were
considered. Respecting the volume constraints, a molecular mass
filter (MW ,350) was applied and 361093 molecules were thus
selected from 3 major providers (Asinex, LifeChemical and
ChemDiv) themselves selected according to the number of filtered
compounds and availability criteria. 3D conformations of the
selected compounds were generated using the ‘‘FAST’’ algorithm
of DiscoveryStudio. Two other filters, acquous solubility features
(24,logSw,0) and refined pharmacophore, were applied to
those molecules and allowed the selection of molecules similar to
PYC with relaxed shape restraints (CatSearch). Then, compounds
were filtered for the Lipinski rule of 5 (well represented in the
selected libraries) in order to extract drug-like molecules. Finally,
compounds were clustered hierarchically (FCFP fingerprint) to
allow classification at different level and define diversity subsets of
to desired sizes. A first experimental screening campaign has
applied to the 1000 diversity subset of the ‘‘ChemDiv, Inc’’
chemical library with no success in finding an inhibitory activity
for TcPRAC, as assayed by polarimetry and by D-amino acid
oxidase- based method. Another set of 374 best-fit compounds was
selected among the proposed options and compounds were
purchased, 330 received, and as previously, no TcPRAC inhibitor
was identified among them (Minoprio, P. and Afshar, M., unpublished).
(ZIP)
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